TVRDTvardi Therapeutics, Inc.同业对比
Tvardi Therapeutics, Inc. 与SIC 2834 行业的逐项对比:市值、估值、增长、盈利能力、质量与总回报,以及在同业组内的排名。所有数值均由引擎从 SEC 申报与延迟行情计算,排名仅为组内排序位置 —— 描述性数据,非投资建议。
完整同业对比
同业组:同 SIC 行业分类 | 公司 | 市值 | 市盈率(TTM) | 市净率 | 市销率 | 营收同比增长 | 净利同比增长 | 息税前利润率 | 净资产收益率 | 投入资本回报率 | 皮氏 F 值 | 一年总回报 | 股息率 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| TVRD本股 | $23M#8 | — | 2.7x#8 | 3.2x#4 | -66.0%#6 | 38.1%#6 | -374.8%#6 | -217.3%#8 | — | — | -95.6%#10 | — |
| NXTC | $28M#2 | — | 2.3x#6 | 1.3x#3 | 252.6%#1 | -0.3%#10 | -257.5%#4 | -459.7%#12 | — | — | 7.9%#2 | — |
| TXMD | $25M#3 | — | 0.9x#4 | 8.4x#6 | 71.6%#2 | 73.9%#1 | -145.3%#3 | -2.1%#1 | -3.8%#1 | 5#1 | 93.8%#1 | — |
| ATOS | $25M#4 | — | 0.9x#3 | 13992.6x#9 | -95.6%#8 | -36.3%#14 | -2112684.9%#9 | -129.6%#5 | — | — | -79.9%#8 | — |
| LTGO | $1.6B#1 | — | — | — | — | — | — | — | — | — | — | — |
| ACTU | $24M#5 | — | 24.3x#14 | — | — | 18.5%#7 | — | -2247.2%#14 | — | — | -85.6%#9 | — |
| LTRN | $23M#6 | — | — | — | — | 17.6%#8 | — | — | — | — | -54.6%#6 | — |
| CLRB | $23M#7 | — | 0.8x#2 | — | — | 51.1%#3 | — | -72.9%#3 | — | — | -54.7%#7 | — |
| COCP | $21M#9 | — | 20.6x#13 | 10.7x#7 | -69.3%#7 | 49.5%#4 | -447.8%#7 | -845.9%#13 | -20.4%#2 | 3#3 | -15.2%#3 | — |
| AYTU | $21M#10 | — | 0.6x#1 | 0.3x#1 | 1.8%#4 | 14.4%#9 | -11.8%#1 | -38.6%#2 | -41.4%#3 | 4#2 | -15.7%#4 | — |
| RKTO | $20M#12 | — | 2.4x#7 | — | — | -52.3%#15 | — | -152.0%#6 | — | — | -53.7%#5 | — |
| MRKR | $20M#13 | — | 1.6x#5 | 5.5x#5 | -46.2%#5 | -13.3%#11 | -363.5%#5 | -100.0%#4 | -1413.6%#6 | — | — | — |
| SHPH | $20M#11 | 349.0x#2 | 6.1x#12 | — | — | -28.2%#12 | — | -350.3%#11 | -507.7%#4 | — | — | — |
| ALLR | $19M#14 | 0.0x#1 | 5.4x#11 | 59.7x#8 | — | 54.2%#2 | -3939.1%#8 | -317.6%#10 | — | — | — | — |
| BFRI | $19M#15 | — | 3.1x#9 | 0.4x#2 | 11.7%#3 | 40.7%#5 | -27.2%#2 | -176.9%#7 | -712.4%#5 | — | — | — |
| ARTL | $18M#16 | — | 3.6x#10 | — | — | -31.1%#13 | — | -257.7%#9 | — | — | — | — |
数值来自 SEC 申报与延迟行情;排名仅为该组内的排序位置 —— 描述性数据,不构成评级或建议。 本表构建超时,仅覆盖该组的一部分成员;排名仅相对于已列出的行,稍后会自动补全。 数据构建于 2026-09-17。
数据来自 SEC XBRL 申报与延迟行情 · 排名为组内排序 · 仅供参考 · 非投资建议